IQVIA’s (NYSE:IQV) Q2 CY2026 Sales Top Estimates, Stock Soars
IQVIA (NYSE:IQV) reported Q2 CY2026 revenue of $4.37 billion, up 8.7% year on year and 1.5% above Wall Street estimates, according to the company. Full-year revenue guidance was $17.38 billion at the midpoint, 0.5% above estimates. Non-GAAP EPS was $3.15, 3.9% above consensus. The stock rose about 8.3% to $231 after results.
How this was made
The 30-second read
Why it matters
Q2 CY2026 results exceeded revenue and EPS expectations, and full-year revenue guidance cleared consensus slightly, but adjusted operating margin contracted and the forward revenue growth outlook is modest.
Market read
A concrete earnings and guidance beat drove an immediate +8.3% stock move, but profitability contraction and low growth expectations may cap upside.
What to watch
The article notes buybacks boosted EPS per share, so traders should separate financial engineering from underlying operating leverage when reassessing forward estimates.
Background
IQVIA is a clinical research services and healthcare data/analytics provider formed from the 2016 Quintiles and IMS Health merger.
Ticker impact
IQVIA beat Q2 CY2026 revenue expectations, with sales up 8.7% to $4.37B and full-year revenue guidance slightly above estimates.
Likely supports continued post-earnings momentum, though follow-through may be limited by adjusted operating margin decline and low single-digit growth expectations.
The article provides concrete Q2 results (revenue, EPS) and guidance versus consensus, plus a specific profitability deterioration (adjusted operating margin down to 13.8% from prior year).
Market effects
Reinforces demand resilience in clinical research/data services, but highlights margin pressure risk when revenue leverage is limited.
No specific regional impact described beyond US-listed trading reaction.
No direct global macro or cross-border regulatory catalyst cited; FX impact is described as not meaningful.
Counterpoint
The revenue beat may not translate into sustained earnings power because adjusted operating margin fell year over year and long-term growth trends remain weak.
Key entities
- public_companyIQVIA
Clinical research services and healthcare data/analytics provider reporting Q2 CY2026 results and full-year guidance.
- executiveAri Bousbib
CEO and chairman quoted on execution and results exceeding expectations.
